Connect with us

INDUSTRIAL HEMP

Axim Biotechnologies Inc (OTCMKTS:AXIM) Finalizes Services Deal With Israel-Based CRO

Published

on

Axim Biotechnologies Inc

Axim Biotechnologies Inc (OTCMKTS:AXIM) has finalized a Services Deal with an Israel-based CRO to commence a clinical proof of concept trial with its Hemp and Gabapentin chewing gum offering to treat restless leg syndrome in patients. The double blind and PK, randomized, single-center Phase II study, which will be performed in Israel by the CRO, will showcase the efficacy of company’s chewing gum product made of Hemp and Gabapentin on around 30 trial participants to cure RLS.

The details

George E. Anastassov, the CEO of Axim Biotechnologies, reported that they are thrilled to be able to deal with an Israeli CRO to perform a pre-and a clinical POC trial for this unmet medical need problem. Israel is advancing in aspect of clinical cannabinoid research and they are thankful for having this chance. Restless Leg Syndrome is a common condition impacting between 3.9% to 14.3% of the U.S. population.

The accessible treatments are not extremely effective and often lead in grave side effects. Anastassov reported that they expect their proprietary treatment modality using gabapentin and cannabinoids in functional chewing gum will show to be effective in lessening the indications of RLS.

Restless leg syndrome, also termed as Willis–Ekbom Disorder, is a condition linked with nocturnal sensorimotor indications, or nocturnal spasms of the muscles of the lesser extremities, that can lead in notable sleep disruption and severe pain. It is a common condition, impacting a projected 3.9% to 14.3% of the U.S. population. RLS can adversely affect a person’s quality of life across numerous domains, such as daytime sleepiness, lower immune function, mood, stress and decreased general health.

In the last trading session, the stock price of Axim declined 0.53% to close the week at $8.16. The decline came at a share volume of 9,116 compared to average share volume of 21,909. After the recent decline, the market cap of firm now stands around $429 million.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.